Complement component 3 (C3) activation fragments (C3 fragments)

Complement C3 activation fragments are the bioactive products generated during the proteolytic cleavage of Complement component 3, which serves as the central convergence point for the classical, lectin, and alternative complement pathways (UniProt P01024). The initial cleavage by C3 convertases produces C3a, a potent anaphylatoxin that triggers local inflammation and leukocyte recruitment, and C3b, an opsonin that facilitates phagocytosis and forms the basis of C5 convertases (PubMed: 27352813). Further degradation of C3b by Factor I results in fragments such as iC3b, C3dg, and C3d, which are critical for bridging innate and adaptive immunity by lowering the threshold for B-cell activation (StatPearls: Complement System). Dysregulation or overactivation of these fragments is a primary driver of tissue damage in various complement-mediated disorders, including Paroxysmal Nocturnal Hemoglobinuria (PNH) and C3 Glomerulopathy (NIH: Rare Diseases). In PNH, C3b opsonization of red blood cells leads to extravascular hemolysis, a process that can be mitigated by C3-targeted therapies. Drugs like pegcetacoplan bind to C3 and its fragments, effectively shutting down the amplification loop of the complement cascade and preventing the downstream formation of the membrane attack complex (DrugBank: Pegcetacoplan). Because C3 is essential for the clearance of encapsulated bacteria, therapeutic targeting of these fragments necessitates strict monitoring and prophylactic vaccination to manage infection risks.

Other names

C3aC3biC3bC3dgC3dComplement C3 cleavage productsC3-derived effectors

Inhibition of C3 cleavage by C3 convertases, stabilization of native C3 to prevent the generation of downstream activation fragments, and blocking the interaction of fragments with their respective receptors.